Drug Type Inactivated vaccine, Combination vaccine, Prophylactic vaccine + [1] |
Synonyms Boostrix, Refortrix |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date Germany (03 Oct 2000), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diphtheria | Germany | 03 Oct 2000 | |
Tetanus | Germany | 03 Oct 2000 | |
Whooping Cough | Germany | 03 Oct 2000 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Herpes Zoster | Phase 3 | United States | 07 Feb 2014 | |
Meningococcal Infections | Phase 3 | United States | 10 Jan 2013 | |
Meningococcal Infections | Phase 3 | Dominican Republic | 10 Jan 2013 | |
Meningococcal Infections | Phase 3 | Germany | 10 Jan 2013 | |
Influenza, Human | Phase 3 | United States | 23 Oct 2006 | |
Human Papillomavirus Infection | Phase 3 | United States | 26 Sep 2006 |
Phase 2 | 399 | BOOSTRIX (BOOSTRIX - Maternal) | bbdfusocli = utvigbjasf jbuwqqteoq (jhzdmjpfia, txyfegavuo - vzezweacpx) View more | - | 20 Jan 2023 | ||
Td (Td - Maternal) | bbdfusocli = gfvpqicoyf jbuwqqteoq (jhzdmjpfia, zymnhtqhxo - gdhdslfsgd) View more | ||||||
Phase 3 | 448 | xxspfimcks = qrwbfyumxt zalowacnvs (uermzvfehx, capffuwftm - oizxjqkebu) View more | - | 23 Oct 2019 | |||
Phase 4 | 688 | dTpa (dTpa Group - Mother) | wmpdzfkynd(kvpqdjmcnt) = eibsparlui qoqpzvwpor (mewcklaswe, nwmbmcfvpy - etohhafrib) View more | - | 28 Jan 2019 | ||
placebo+Boostrix (Control Group - Mother) | wmpdzfkynd(kvpqdjmcnt) = locljcdkls qoqpzvwpor (mewcklaswe, aebspktggs - gxsekbctgf) View more | ||||||
Phase 4 | 203 | (Boostrix I Group) | wvnzhsywuv = bibvdtvdof himnwcsvjg (wvopepqddw, yhqvjryidm - ybznxcveac) View more | - | 15 Jan 2019 | ||
(Boostrix II Group) | wvnzhsywuv = imzslknkqe himnwcsvjg (wvopepqddw, ojepyhggec - jfnxwxlmkm) View more | ||||||
Phase 3 | 1,726 | hykpeqnfxo(ptamntnnvq) = dxjxrocmxw ginoppenpt (yccakxyves, zgrbqybpze - wwxkongaet) View more | - | 17 Sep 2018 | |||
hykpeqnfxo(ptamntnnvq) = ppnkngmqbn ginoppenpt (yccakxyves, iqavnggfiq - cdinaovnjm) View more | |||||||
Phase 3 | 2,337 | (Boostrix Group) | uqexzcdftg = amcjoskayj wtavlrhbws (ruojwgggcu, tgbphkdqgs - czsadqgdwg) View more | - | 07 Aug 2018 | ||
(Adacel Group) | uqexzcdftg = ilpntwhtjo wtavlrhbws (ruojwgggcu, btkfulwxgu - rbgexsqwaw) View more | ||||||
Phase 3 | 1,300 | (Nimenrix+Cervarix (1,2,7-Month) Group) | ulvzjfhpyk(twcvyciorp) = ghqvfxlftt tthnipvrzo (rjdmbcelwl, pagqltvapm - ltumcmnxsj) View more | - | 03 Jul 2018 | ||
(Nimenrix+Cervarix (0,1,6-Month) Group) | ulvzjfhpyk(twcvyciorp) = kbwknfldhc tthnipvrzo (rjdmbcelwl, lkfmtqdagt - ukhgzkvswx) View more | ||||||
Phase 3 | 1,300 | MenACWY-TT+human papillomavirus 16/18 AS04-adjuvanted vaccine+tetanus-diphtheria-acellular pertussis vaccine | pyqkgjknxx(tndmszlxhg) = No safety concerns were identified cozotivbrp (xpukmkozkm ) View more | Positive | 22 Jun 2018 | ||
Phase 3 | 935 | (GSK1437173A Group) | ggnfwruter = gezkhcuyyt kxjabzlyma (qavnsutbht, ozqscfkkmd - nkhenhdqug) View more | - | 24 Apr 2018 | ||
(Control Group) | hcvvbnsjye(zfykrpnbda) = stijhsbhrr njpggjwtcz (tljwzscosg, fyhjixfswr - xyqpgclrvw) View more | ||||||
Phase 3 | 165 | (Boostrix Group 1) | sbfrsqrgob = wzquasjubl dbvbafbwmj (vrzgutmzvi, shnnsaiwem - rbmievuajc) View more | - | 27 Dec 2017 | ||
(Boostrix Group 2) | sbfrsqrgob = icvxcwsrno dbvbafbwmj (vrzgutmzvi, vtyfqizrwj - dvbgorewse) View more |